CKD patients at out patient department of Phramongkutklao hospital with vitamin D deficiency or insufficiency [25(OH)D<30 ng/mL]. Ergocalciferol,
Conditions
Interventions
given ergocalciferol 60,
000IU
single dose on every Monday
day,
for 12 weeks. Main outcome measure were serum 25(OH)D concentrations,
serum calcium,
serum phosphate,
and parathyroid level at 12 weeks after enrolled,given ergocalciferol 20,
000 IU on every Monday,
Friday for 12 weeks. Main outcome measure were serum 25(OH)D concentrations,
and parathyroid level at 12 weeks after enrolled
Active Comparator Drug,Active Comparator Drug
Nonsplit dose of ergocalciferol at 60,
000 IU ,split dose of ergocalciferol at 60,
000 IU
Sponsors
None
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: CKD non dialysis Age>18 years Serum 25(OH)D level 30 ng/mL
Exclusion criteria
Exclusion criteria: primary or tertiary hyperparathyroidism On ergocalciferol On active form of vitamin D Ca> 10.5 mg/dL Phosphate> 5.5 mg/dL Cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum 25(OH)D in CKD patient. 12 weeks Level of serum 25(OH)D | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety outcome 8, 12 weeks Serum calcium and phosphate | — |
Countries
Thailand
Contacts
Public ContactNaowanit Nata
Phramongkutklao Hospital and College of Medicine
Outcome results
None listed